# Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs

> **NCT02294006** · PHASE2 · UNKNOWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 26 (actual)

## Conditions studied

- Well Differentiated Pancreatic Endocrine Tumor

## Interventions

- **DRUG:** Everolimus plus Octreotide LAR plus Metformin

## Key facts

- **NCT ID:** NCT02294006
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-06
- **Primary completion:** 2021-06
- **Final completion:** 2021-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02294006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02294006, "Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02294006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*